Microtrast

Barium sulfate, the active ingredient in Microtrast, is a contrast media presented as an oral suspension for gastrointestinal imaging use. It coats the lumen of the GI tract, providing radiopaque contrast that enhances X‑ray visualization during procedures such as barium swallow and enema studies.

GNH USA supplies Microtrast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for global distribution. The company provides dedicated technical support and comprehensive documentation for regulatory submissions.

Microtrast is a barium‑based contrast agent employed in gastrointestinal imaging procedures to improve radiographic visualization.

- Barium swallow study: enhances visualization of the esophagus and pharynx, allowing detection of motility disorders, strictures, and structural lesions. - Barium enema: provides uniform contrast coating of the colon and rectum, facilitating identification of polyps, tumors, diverticula, and inflammatory changes. - Upper gastrointestinal series: outlines the stomach and duodenum, aiding diagnosis of ulcers, masses, and anatomical abnormalities.

Adverse reactions to Microtrast are generally related to the gastrointestinal tract and occasional systemic responses.

Common Side Effects: - Nausea: mild to moderate sensation of queasiness after ingestion. - Abdominal cramping: transient discomfort in the stomach or intestines. - Constipation: reduced bowel movements that may persist for several hours. - Diarrhea: loose stools occurring shortly after the procedure.

Serious or Rare Side Effects: - Aspiration pneumonia: risk if the suspension is inhaled into the lungs. - Severe allergic reaction: includes rash, itching, swelling, or anaphylaxis. - Bowel obstruction or perforation: possible in patients with pre‑existing strictures or lesions.

Before using Microtrast, certain precautions should be observed to minimize risks and ensure optimal imaging quality.

- Assess for gastrointestinal obstruction: confirm absence of known strictures, perforations, or severe motility disorders. - Review patient allergy history: avoid use in individuals with known hypersensitivity to barium sulfate or other contrast agents. - Ensure adequate hydration: advise patients to drink fluids after the study to promote barium elimination. - Avoid concurrent use of high‑dose laxatives immediately before the exam, as they may diminish coating effectiveness. - Pregnancy considerations: evaluate risk‑benefit ratio and use only when essential for maternal or fetal diagnosis. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Barium sulfate has limited systemic absorption, but certain co‑administered agents can affect its performance or increase adverse effects.

Major Interactions (Avoid): - Use with high‑dose laxatives or bowel‑cleansing agents immediately before administration: may reduce coating and image quality. - Co‑administration with oral iron supplements: can cause precipitation, compromising radiographic contrast.

Moderate Interactions (Monitor Closely): - Anticholinergic medications: may increase risk of constipation when combined with barium suspension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal irritation. - Oral antibiotics: may alter gut flora and affect barium transit time.